A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma

被引：0
|
作者：
Shuji Hiramoto
Ken Kato
Hirokazu Shoji
Natsuko Okita
Atsuo Takashima
Yoshitaka Honma
Satoru Iwasa
Tetsuya Hamaguchi
Yasuhide Yamada
Yasuhiro Shimada
Narikazu Boku
机构：
[1] National Cancer Center Hospital,Gastrointestinal Medical Oncology Division
[2] Mitsubishi Kyoto Hospital,Department of Clinical Oncology and Palliative Medicine
来源：
International Journal of Clinical Oncology | 2018年 / 23卷
关键词：
Metastatic/recurrent esophageal cancer; First-line chemotherapy; 5-Fluorouracil + cisplatin; Prognostic factors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：466 / 472
页数：6
相关论文
共 50 条
  • [21] Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
    Fang, Rui
    Wang, Suiqiong
    Liu, Yongqian
    Xu, Jun
    ADVANCES IN THERAPY, 2023, 40 (03) : 1019 - 1030
  • [22] Cost-Effectiveness Analysis of Toripalimab Plus Paclitaxel and Cisplatin as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma
    Rui Fang
    Suiqiong Wang
    Yongqian Liu
    Jun Xu
    Advances in Therapy, 2023, 40 : 1019 - 1030
  • [23] THE USE OF CISPLATIN PLUS 5-FLUOROURACIL CHEMOTHERAPY IN AN UNSELECTED GROUP OF PATIENTS WITH RECURRENT SQUAMOUS-CELL CARCINOMA OF THE HEAD AND NECK
    OBRIEN, M
    SCHOFIELD, JB
    LORENTZOS, A
    MOORE, J
    ATKINSON, H
    HENK, JM
    MACLENNAN, KA
    GORE, ME
    ORAL ONCOLOGY-EUROPEAN JOURNAL OF CANCER PART B, 1994, 30B (04): : 265 - 267
  • [24] SHR-1701 plus chemotherapy as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).
    Wang, Yi
    Liu, Hong
    Wang, Qingwei
    Qiao, Naian
    Wang, Jianbo
    Tan, Bingxu
    Cheng, Bo
    Chu, Yunxia
    Li, Huajun
    Cheng, Yufeng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 363 - 363
  • [25] A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum
    Kentaro Yamazaki
    Shuichi Hironaka
    Narikazu Boku
    Hirofumi Yasui
    Akira Fukutomi
    Takayuki Yoshino
    Yusuke Onozawa
    Noriaki Hasuike
    Tetsuya Inui
    Yuichiro Yamaguchi
    Hiroyuki Ono
    International Journal of Clinical Oncology, 2008, 13 : 150 - 155
  • [26] A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum
    Yamazaki, Kentaro
    Hironaka, Shuichi
    Boku, Narikazu
    Yasui, Hirofumi
    Fukutomi, Akira
    Yoshino, Takayuki
    Onozawa, Yusuke
    Hasuike, Noriaki
    Inui, Tetsuya
    Yamaguchi, Yuichiro
    Ono, Hiroyuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2008, 13 (02) : 150 - 155
  • [27] Cost-Effectiveness Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma in China
    Zhou, Chongchong
    Wei, Jingxuan
    Xu, Kai
    Lin, Yingtao
    Zhang, Lingli
    Li, Xin
    RISK MANAGEMENT AND HEALTHCARE POLICY, 2023, 16 : 2447 - 2458
  • [28] Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME).
    Vermorken, J. B.
    Mesia, R.
    Vega-Villegas, M. E.
    Remenar, E.
    Hitt, R.
    Kawecki, A.
    Rottey, S.
    Zabolotnyy, D.
    Erfan, J.
    Amellal, N.
    Antwerpen, U. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 289S - 289S
  • [29] Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
    Liu, Yanhong
    Shao, Rong
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [30] Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
    Chen, Dan
    Cheng, Jue
    Yang, Kai
    Ma, Yue
    Yang, Fang
    ONCOTARGETS AND THERAPY, 2013, 6 : 1507 - 1514
12345